33 results about "Methylcobalamin" patented technology

Disclosed are pharmaceutical compositions comprising azelastine or a pharmaceutically acceptable salt of azelastine and methylcobalamin. Also disclosed are methods of using the pharmaceutical compositions to treat patients suffering from Alzheimer's disease or Parkinson's disease.

The invention relates to a method for producing mecobalamin by using a micro-channel reactor, which comprises the following steps: firstly, introducing a reaction mixed solution of cyanocobalamin, cobalt chloride, sodium borohydride and purified water into a first micro-channel reactor for reduction reaction; the obtained cyanocobalamin solution in the reduction state is introduced into a second microchannel reactor to be subjected to a methylation reaction with a trimethylsulfoxide iodide solution, and finally, an obtained mecobalamin solution is subjected to post-treatment to obtain a finished product. Compared with the prior art, the micro-channel reactor is used for continuous production, the mass and heat transfer effect is good, the reaction temperature can be accurately controlled, side reactions are further reduced, and the product quality is effectively improved.

The invention discloses a preparation method of an amniotic membrane loaded with procyanidine and mecobalamine, which comprises the following steps: soaking an amniotic membrane in a solution containing procyanidine, mecobalamine and N-hydroxysuccinimide, and reacting to obtain the amniotic membrane loaded with procyanidine and mecobalamine. The amniotic membrane is selectively loaded with procyanidine and mecobalamin, has the functions of resisting inflammation and bacteria and promoting corneal epithelium and nerve repair, and solves the problem that the repair promoting function of the treated amniotic membrane is reduced.

The application provides a kind of medicine composition for treating muscle and bone disease and its application, belong to medical technology field.The medicine composition includes the following weight parts components: compound angelica injection 5-10 parts, kadsura injection 5-10 parts, wild medlar injection 5-10 parts, methylcobalamin injection 5-10 parts;It can also be selectively added vitamin B1 injection, vitamin B12 injection, yellow Chinese wax injection or bone peptide injection.The composition of the application is administered by acupoint injection or intramuscular injection, utilizes the synergistic effect of multiple traditional Chinese medicine injection and western medicine injection, reaches the comprehensive treatment effect of promoting blood circulation to remove blood stasis, dispelling wind to stop pain, nerve nutrition.Clinical experiments show that the application has significant effect on lumbar disc herniation, cervical spondylosis, shoulder periarthritis, knee osteoarthritis, femoral head necrosis, osteoporosis and the like, and the total effective rate is more than 95%, with fast effect, low recurrence rate, and no hormone-related side effects, suitable for patients of all ages.

1.The name of the design product: packaging box (methylcobalamin tablets). 2.The use of the design product: used as a packaging box for medicines. 3.The design points of the design product: the combination of shape, pattern and color. 4.The picture or photo that best shows the design points: perspective view. 5.The design claimed contains color.

The invention discloses a mecobalamin composition. The mecobalamin composition comprises mecobalamin, a stabilizer, a suspending aid and an adsorbent. The applicant can improve the stability of mecobalamin to a certain extent by adopting edetate disodium or citric acid as a stabilizer, and can uniformly disperse mecobalamin in the solid dispersion through spray drying to construct a physical barrier, thereby improving the light instability of mecobalamin.

This invention relates to the field of pharmaceutical analysis and detection technology, and proposes a method for detecting related substances in methylcobalamin tablets. The method employs reversed-phase high-performance liquid chromatography (RP-HPLC) with an ultraviolet (UV) detector. The chromatographic conditions of the RHPLC-UV detector method include: mobile phases A and B; mobile phase A is a 92:8 mixture of potassium dihydrogen phosphate solution and acetonitrile, and mobile phase B is a 92:8 mixture of acetonitrile and water; gradient elution is used. This technical solution solves the problem of inaccurate detection of related substances in methylcobalamin tablets in related technologies.

This invention discloses a strain of *Lactobacillus paracasei* capable of converting cyanocobalamin and promoting its absorption, thereby enhancing brain nerve repair and improving cognition, and its postbiotic, belonging to the fields of microbial technology and pharmaceutical technology. The *Lactobacillus paracasei* CCFM1527 and its prepared postbiotic provided by this invention promote the growth of vitamin B1 in the host. 12 The neuroprotective effects of upregulating the expression of absorption receptors and converting CN-CbI to methylcobalamin include: (1) promoting the upregulation of Amnionless expression in intestinal cells (Caco-2); (2) converting CN-CbI to methylcobalamin; and (3) promoting the upregulation of Amnionless expression in mouse ileum. AMN Upregulation of gene expression (4) significantly increased the levels of vitamin B in mice. 12 (5) Significantly promotes the expression of MBP and PSD-95 proteins in mice; (6) Improves the decline in cognitive ability in mice, and has great application prospects.

The present invention belongs to the field of pharmaceutical preparations. Specifically, the present invention relates to a composition for treating pain caused by nerve damage. A combination of melogabalin or a pharmaceutically acceptable salt thereof and methylcobalamin in a certain ratio can produce an analgesic enhancement or synergistic effect on neurogenic pain. The preparation of an orally disintegrating tablet containing melogabalin or a pharmaceutically acceptable salt thereof and methylcobalamin can also improve patient medication compliance, improve memory, and alleviate symptoms associated with neurogenic pain, thus having excellent application value.

This invention provides a pharmaceutical composition combining azelastine and methylcobalamin. [Solution] An orally administered pharmaceutical composition is provided, comprising azelastine or a pharmaceutically acceptable salt of azelastine, methylcobalamin, and one or more pharmaceutically acceptable excipients, wherein the pharmaceutical composition is formulated as a capsule, caplet, tablet, or pill configured for oral administration and absorption in the gastrointestinal tract, and the azelastine or a pharmaceutically acceptable salt of azelastine and methylcobalamin are present together in the pharmaceutical composition in a therapeutically effective daily dose for treating Alzheimer's disease or Parkinson's disease in human patients.

The present invention provides a novel food and drink containing at least one cobalamin selected from the group consisting of cyanocobalamin, hydroxocobalamin, adenosylcobalamin, methylcobalamin, and sulfitocobalamin. According to an embodiment of the present invention, there is provided a bottled beverage containing carnosine and at least one cobalamin selected from the group consisting of cyanocobalamin, hydroxocobalamin, adenosylcobalamin, methylcobalamin, and sulfitocobalamin, wherein the content of carnosine is 0.70-15 mg / mL and the content of the at least one cobalamin is 0.005-1 µm / mL.

The present application discloses a methylcobalamin tablet, which contains, by weight ratio: 0.8 - 1.2 parts of mecobalamin, 15 - 18 parts of starch, 55 - 65 parts of microcrystalline cellulose, 100 - 110 parts of lactose, 0.4 - 0.5 parts of calcium stearate, and 8 - 10 parts of coating agent. Among them, the particle size range of the mecobalamin after micronization is 0.60μm ≤ D10 ≤ 0.90μm, 5.2μm ≤ D50 ≤ 6.3μm, 20μm ≤ D90 ≤ 26.5μm, and the particle size range of the lactose after micronization is 1.0μm ≤ D10 ≤ 2.5μm, 6.5μm ≤ D50 ≤ 10.5μm, 23μm ≤ D90 ≤ 35μm.

The invention relates to a method for producing hydroxycobalamin salt by using a microchannel reactor, which comprises the following steps of: performing illumination reaction by using mecobalamin as a raw material and zinc as a catalyst through the microchannel reactor, separating and treating the obtained hydroxycobalamin salt solution, and finally purifying and treating to obtain a finished product. Compared with the prior art, the micro-channel reactor is used for production, reactants can be rapidly heated to the reaction temperature, and the temperature is kept stable, so that the reaction efficiency and the yield of a target product are improved, the generation of impurities is greatly inhibited, and the quality of the product is effectively improved.

The invention relates to the technical field of medicine detection equipment, and discloses a mecobalamin tablet production line multi-station synchronous quality detection device which comprises a discharging structure, a detection structure, a plurality of feeding structures and a plurality of discharging structures. The detection structure is arranged on the right side of the discharging structure, the multiple feeding structures are arranged on the right side of the detection structure at equal intervals and symmetrically located on the front side and the rear side of the detection structure correspondingly, and the multiple discharging structures are arranged on the feeding frame structure correspondingly. Multi-station synchronous double-face detection is achieved, the detection efficiency and the coverage rate are greatly improved, directional screening and collecting are achieved, accurate separation of qualified products and unqualified products is achieved, a conveying structure can be flexibly adjusted, and the space utilization rate and the equipment layout reasonability are improved; accessories can be flexibly replaced, the adaptability and the generalization degree of equipment are greatly improved, full-process automatic operation is achieved, and manual intervention and the equipment failure rate are reduced.

The invention provides a mecobalamin sustained-release micro-tablet which is composed of a sustained-release layer, a release layer and a coating layer, the sustained-release layer and the release layer form a double-layer release system, the release speed of mecobalamin is effectively controlled by controlling the drug proportion of the sustained-release layer and the release layer, the problem that drug release is fast due to the small size and the large specific surface area of the micro-tablet is solved, and the mecobalamin sustained-release micro-tablet is suitable for large-scale production. And the micro-tablet realizes long-time, continuous and stable release of the medicine. The mecobalamin sustained-release micro-tablet provided by the invention has the diameter of 1-3mm and the tablet weight of 20-60mg, and compared with a common tablet, the sustained-release micro-tablet can reduce the administration frequency of a patient, realizes administration once a day, improves the compliance of the patient, and can meet the medication requirements of children, old people, patients with dysphagia and the like.

This invention discloses a sustained-release membrane for postoperative treatment of diabetic peripheral neuropathy and its preparation method. The sustained-release membrane comprises, from the outside in, a PLGA nanofiber outer layer containing tacrolimus and magnesium hydroxide nanoparticles, a glucose-responsive hydrogel middle layer containing insulin and glucose oxidase / catalase, and a PCL-oriented nanofiber inner layer containing methylcobalamin. The layers are connected by a polydopamine interface layer, and the outermost surface of the outer layer is coated with a hyaluronic acid anti-adhesion coating. Insulin, as a local neurotrophic factor, directly activates the PI3K / Akt / mTOR and ERK / MAPK signaling pathways, promoting axonal regeneration and myelin repair. The sustained-release membrane integrates three major functions: immunomodulation / anti-inflammation, glucose-responsive insulin neurotrophic delivery, and sustained nerve regeneration promotion. It prevents postoperative nerve re-adhesion through a spatiotemporal sequential drug release strategy. All components are biodegradable and do not require secondary surgery for removal.

The present invention belongs to the field of pharmaceutical research technology, and specifically relates to a methylcobalamin nanofunctionalized collagen polysaccharide sponge and its application. The methylcobalamin nanofunctionalized collagen polysaccharide sponge is prepared according to the following steps: cross-linking is performed using the carboxyl groups on the surface of collagen with the amino groups of chitosan, and then cross-linking with hyaluronic acid to obtain a bioactive material; hydrothermal reaction is performed using methylcobalamin as a raw material to obtain methylcobalamin nanodots; methylcobalamin nanodots are mixed with the bioactive material for electrostatic adsorption to obtain a collagen polysaccharide sponge. The collagen polysaccharide sponge provided by the present invention can solve the multiple challenges faced by the application of methylcobalamin molecules in the inflammatory site of spinal cord injury, such as easy diffusion degradation, delivery barriers and microenvironment interference, and achieve long-term inflammation / immune microenvironment regulation, targeted polarization of BV2 cells and efficient nerve regeneration and other key technical problems, and has good biodegradability and cell adaptability.

The invention provides an enteric-coated tablet for treating neuritis and a preparation method of the enteric-coated tablet. The enteric-coated tablet is prepared from the following components in percentage by weight: 0.01%-1% of mecobalamin, 60%-80% of butanedisulfonic acid adenosyl methionine, 10%-30% of a diluent, 4%-9% of an adhesive, 1%-5% of a disintegrating agent, 0.1%-1% of a lubricant and 8%-16% of an enteric-coated material. The enteric-coated tablet disclosed by the invention is simple in production process, universal in production equipment and low in cost, mainly overcomes the defect of large in-vivo absorption difference, and has a remarkable curative effect on treating neuritis.

1.The name of the design product: packaging box (Aleylinum methylcobalamin tablets). 2.The use of the design product: used for the outer packaging of medicines. 3.The design points of the design product: the combination of shape, pattern and color. 4.The picture or photo that best shows the design points: front view. 5.The design claimed contains color.

The invention discloses an anti-aging compound nutritional composition as well as a preparation method and application thereof, and belongs to the technical field of foods. The composition is prepared from the following components in unit dose: 150 to 250 mg of nicotinamide ribose, 10 to 30 mg of pyrroloquinoline quinone disodium salt, 100 to 200 mg of quercetin phospholipid complex, 300 to 500 [mu] g of (6S)-5-calcium methyltetrahydrofolate, 30 to 80 [mu] g of methyl cobalamin, 5 to 15 mg of pyridoxine hydrochloride, 50 to 100 mg of radix astragali seu hedysari extract, 50 to 100 mg of fructus lycii extract, 50 to 100 mg of rhizoma polygonati extract and auxiliary materials. Through the synergistic effect of the nutrients and the traditional Chinese medicine extracts, NAD < + > improvement, mitochondrial protection, oxidation resistance and energy metabolism regulation are achieved, and the nutrient composition has novelty, safety and industrial practicability and can be used for preparing anti-aging nutritional supplements or health-care foods.

This invention discloses a quantitative methylcobalamin capsule filling machine, relating to the field of methylcobalamin capsule processing technology. It includes a main support frame with a filling support frame fixedly connected to one side. A lower cover for a filling plate is rotatably connected above the filling support frame, and a upper cover for a filling plate is slidably connected above the lower cover. A ring-shaped array of outer filling tubes is fixedly installed inside the upper cover, and inner filling tubes corresponding to the number and position of the outer filling tubes are fixedly connected above the lower cover. The outer diameter of the inner filling tubes is equal to the inner diameter of the outer filling tubes. The height of the accommodating space between the inner and outer filling tubes is adjusted by the relative sliding between the upper and lower covers, thereby changing the amount of powder that can be filled each time. A drive motor rotates the filling plate, causing multiple filling tubes to pass sequentially under the inner rods of plungers at different heights, achieving graded compaction filling. This allows for precise control of the single filling amount, adapting to the production needs of different capsule specifications and avoiding uneven filling due to powder clumping or voids.

To provide a novel food and drink containing at least one cobalamin selected from the group consisting of cyanocobalamin, hydroxocobalamin, adenosylcobalamin, methylcobalamin, and sulfitecobalamin.SOLUTION: According to one aspect of the present invention, a bottled beverage is provided containing carnosine and at least one cobalamin selected from the group consisting of cyanocobalamin, hydroxocobalamin, adenosylcobalamin, methylcobalamin, and sulfitecobalamin, wherein the content of carnosine is 0.70 to 15 mg / mL, and the content of the at least one cobalamin is 0.005 to 1 μg / mL.SELECTED DRAWING: None

Disclosed is a pharmaceutical composition in one or more of a solid dosage form, a powder form, a liquid-filled capsule, and a softgel capsule for preventing long-term COVID-19 morbidity. The pharmaceutical composition includes a therapeutically effective amount of a mixture of: nicotinic acid, ascorbic acid, vitamin D, zinc picolinate, selenium, luteolin, methylcobalamin (B12), taurine, turmeric extract (>95% Curcumin), R-alpha-lipoic acid, d1-alpha-tocopheryl acetate (Vitamin E), Co-enzyme Q10 (CoQ10), acetyl-L-carnitine, pyrroloquinoline quinone (PQQ), 5-MTHF methyl folate, lutein, zeaxanthin, thiamine (B1), riboflavin (B2), biotin (B7), pyridoxine hydrochloride (B6), calcium ascorbate, magnesium bisglycinate, copper bisglycinate, panthothenate (B5), betain Hydrochloride, vitamin K2, and boron glycinate.

The invention belongs to the technical field of medicine research, and particularly relates to a mecobalamin nano-functionalized collagen polysaccharide sponge and application thereof. The mecobalamin nano-functionalized collagen polysaccharide sponge is prepared according to the following steps: cross-linking carboxyl on the surface of collagen with amino of chitosan, and cross-linking with hyaluronic acid to obtain a bioactive material; the preparation method comprises the following steps: carrying out hydrothermal reaction by taking mecobalamine as a raw material to obtain mecobalamine nanodots; and mixing the mecobalamin nanodots with a bioactive material, and carrying out electrostatic adsorption to obtain the collagen polysaccharide sponge. The collagen polysaccharide sponge provided by the invention can solve multiple challenges of easy diffusion and degradation, delivery barrier, microenvironment interference and the like faced by application of mecobalamine molecules in spinal cord injury inflammation parts, and realizes key technical problems in multiple aspects of long-term inflammation / immune microenvironment regulation, targeted polarization of BV2 cells, efficient nerve regeneration and the like; the biodegradability and the cell adaptability are relatively good.

The invention provides a post-treatment purification process method of mecobalamin. The post-treatment purification process method comprises the following steps: (1) preparing a mecobalamin reaction solution; (2) filtering the mecobalamin reaction solution, and purifying through a high-pressure purification column to obtain a purified solution; (3) carrying out adsorption and desorption on the purified liquid through a resin column; (4) crystallizing and refining the desorption solution to obtain pure mecobalamin, and the like. By optimizing a mecobalamin post-treatment purification process, the impurity content is reduced, the yield of mecobalamin is improved, and the purification method is simple and convenient to operate and convenient for industrial production.

The present invention relates to a material-supplementing method for increasing tylosin fermentation units. The method uses Streptomyces fradiae as a fermentation strain, and comprises inoculating a seed liquid into a fermentation tank filled with a liquid fermentation culture medium and using a material-supplementing fermentation process to produce tylosin: at fermentation hour 12, adding a disodium malonate solution to react for 2 hours, then adding a VB12 solution, and during fermentation hours 30-130, adding a methylcobalamin solution at intervals of 12 hours. Using the material-supplementing process effectively increases tylosin fermentation units by 2-4% or more, and the method is suitable for industrial production.

The purpose of the present invention is to provide a pharmaceutical composition for preventing or treating dementia, and a method for preventing or treating dementia.　The present invention pertains to: a pharmaceutical composition for preventing or treating dementia, the pharmaceutical composition comprising methylcobalamin as an active ingredient and being administered parenterally; a prevention or treatment method for preventing or treating dementia; and use.

The invention provides a compound, a culture solution and a method for improving in-vitro maturation efficiency of mammal oocytes, and belongs to the technical field of in-vitro fertilization. The invention provides a compound for improving in-vitro maturation efficiency of mammal oocytes. The compound is prepared from the following components: betaine, L-cystine, a glycine zinc chelate, nicotinamide, pyridoxine hydrochloride, riboflavin, 5-methyltetrahydrofolic acid and cobalamin. The invention also provides a culture solution containing the compound, the culture solution is used for culturing in an oocyte in-vitro maturation stage, and the compound or the culture solution can be used for remarkably improving the blastocyst formation rate, the embryo quality and the pregnancy rate after transplantation by accurately regulating and controlling the metabolic microenvironment in the oocyte maturation stage; the large-scale production requirements of cattle and sheep embryos can be met, and the popularization and application of an in-vitro embryo technology are promoted.

The invention discloses a method for detecting 34-methyl mecobalamin in a mecobalamin bulk drug, and belongs to the technical field of pharmaceutical analys.The method comprises the steps that high performance liquid chromatography is utilized, a chromatographic column with octadecylsilane chemically bonded silica as filler is adopted, and a mobile phase A is composed of 0.03 mol / L monopotassium phosphate solution and acetonitrile according to the volume ratio of 90: 10; a mobile phase B is composed of a 0.03 mol / L monopotassium phosphate solution and acetonitrile according to the volume ratio of 30: 70, the flow rate of the mobile phase is 1.0 ml / min, gradient elution is adopted, a detector is an ultraviolet absorption detector, the detection wavelength is 342 nm, the sample size is 20 microliters, and the column temperature of a chromatographic column is 40 DEG C. The method is high in sensitivity, good in repeatability, accurate in determination result, good in specificity and linear relation and suitable for industrial production. The method can be used for quality control of 34-methyl mecobalamin in mecobalamin.

The utility model relates to the field of mecobalamin tablet packaging, and discloses a full-automatic packaging machine for mecobalamin tablet production, which comprises an outer frame, the top of the outer frame is fixedly connected with a fixed box, two ends of the inner part of the fixed box are fixedly connected with material guiding plates, the inner parts of the outer frame and the fixed box are respectively provided with a material inlet, and the material inlet is communicated with the material guiding plates. A discharging pipe is fixedly connected to the upper portion of the inner wall of the outer frame, an electric valve is fixedly connected to the interior of the discharging pipe, and a welding assembly is arranged below the electric valve. According to the packaging bag sealing device, packaging materials in the discharging pipe are sent out by opening an electric valve, a welding plate is driven by an electric push rod to move, when the welding plate is connected with a second fixing plate, the effect of sealing the bottom of a packaging bag can be achieved, and a sliding block is driven by an electric sliding rail to move; the sliding block drives the moving block to move, the moving block moves to drive the welding plate to move, and the welding plate moves to achieve the effect of pulling off a sealed finished product.